ArticleFrontiers in oncology2025
Surveillance of
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Patients and methods: We retrospectively examined 119 transplanted patients who had a smoking history above 20 pack-years. These patients underwent yearly evaluations by an ear-nose-throat specialist. Results: Twelve of them (10.1%) were diagnosed with head and neck cancer. The most significant risk factor for developing head and neck cancer was having been transplanted for alcoholic liver disease. Of the 12 diagnosed cases, six cases were diagnosed at an early-intermediate stage (stages 0-II), five were at an advanced stage (including one patient who was diagnosed at his first surveillance visit and two who did not attend the surveillance visits), and tumor stage was unknown in one case. Three patients had cancer recurrences, all of them had continued smoking after their initial diagnosis. The five-year actuarial survival rate after the diagnosis of head and neck cancer was 65.6%. Discussion: Annual surveillance for head and neck cancer may allow for early diagnosis and better survival rates after cancer diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.